Esta publicación examina la hepatitis viral y el uso de drogas en Europa, centrándose en la promoción del tratamiento entre las personas que se inyectan drogas y el fin de la criminalización de estas. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas. 

This publication has been produced with the financial support of the Drug Prevention and Information Programme (DPIP) of the European Union. The contents of this publication are the sole responsibility of the authors and can in no way be taken to reflect the view of the European Commission. The publication charges for this supplement were funded by AbbVie as an unresitricted grant to Rigshospitalet, the University of Copenhagen, Denmark. 

Introduction   Open Access

Hepatitis – a devastating epidemic in Europe

Jeffrey V Lazarus, Kevin A FentonBMC Infectious Diseases 2014, 14(Suppl 6):S1 (19 September 2014)

Commentary   Open Access

No strategy to meet the HCV epidemic

Olav Dalgard, Stefan MaussBMC Infectious Diseases 2014, 14(Suppl 6):S2 (19 September 2014)

Commentary   Open Access

Improved hepatitis C screening and treatment in people who inject drugs should be a priority in Europe

Achim Kautz, Lilyana Chavdarova, Margaret WalkerBMC Infectious Diseases 2014, 14(Suppl 6):S3 (19 September 2014)

Commentary   Open Access

Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C

Chris Ford, Juliet BressanBMC Infectious Diseases 2014, 14(Suppl 6):S4 (19 September 2014)

Commentary   Open Access

A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients

Maria Phelan, Catherine CookBMC Infectious Diseases 2014, 14(Suppl 6):S5 (19 September 2014)

Commentary   Open Access

A national multidisciplinary healthcare network for treatment of hepatitis C in people who inject drugs in Slovenia

Mojca MaticicBMC Infectious Diseases 2014, 14(Suppl 6):S6 (19 September 2014)

Commentary   Open Access

The successful implementation of Scotland’s Hepatitis C Action Plan: what can other European stakeholders learn from the experience? A Scottish voluntary sector perspective

 Leon Wylie, Sharon Hutchinson, David Liddell, Nicola RowanBMC Infectious Diseases 2014, 14(Suppl 6):S7 (19 September 2014)

Commentary   Open Access

Improving the quality of needle and syringe programmes: an overlooked strategy for preventing hepatitis C among people who inject drugs

Astrid LeichtBMC Infectious Diseases 2014, 14(Suppl 6):S8 (19 September 2014)

Commentary   Open Access

Consensus for the integrated management of hepatitis C in Portugal

Ricardo LeiteBMC Infectious Diseases 2014, 14(Suppl 6):S9 (19 September 2014)

Commentary   Open Access

A perspective from drug user organisations on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’

Antonio Corbacho, Manuel Rivera, Francisco Trujillo, Maite Martí, José Carbonell, Francisco Fernández, Alexandre Rosselló, Jordi Perramon, Jaume Salse, Ignacio RamosBMC Infectious Diseases 2014, 14(Suppl 6):S10 (19 September 2014)

Commentary   Open Access

A policy-maker’s perspective on ‘ECDC and EMCDDA guidance: prevention and control of infectious diseases among people who inject drugs’

Joan Colom I FarranBMC Infectious Diseases 2014, 14(Suppl 6):S11 (19 September 2014)

Research   Open Access 

Hepatitis C virus seroprevalence among people who inject drugs and factors associated with infection in eight Russian cities

Robert Heimer, Ksenia Eritsyan, Russell Barbour, Olga S LevinaBMC Infectious Diseases 2014, 14(Suppl 6):S12 (19 September 2014)

Review   Open Access

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

Lars Peters, Amanda Mocroft, Jens Lundgren, Daniel Grint, Ole Kirk, Jürgen RockstrohBMC Infectious Diseases 2014, 14(Suppl 6):S13 (19 September 2014)

Research   Open Access

Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries

Mojca Maticic, Jerneja Videcnik Zorman, Sergeja Gregorcic, Eberhard Schatz, Jeffrey V LazarusBMC Infectious Diseases 2014, 14(Suppl 6):S14 (19 September 2014)

Research   Open Access

Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey

Alexander Spina, Irina Eramova, Jeffrey V LazarusBMC Infectious Diseases 2014, 14(Suppl 6):S15 (19 September 2014)

Research   Open Access

A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

Jeffrey V Lazarus, Ida Sperle, Mojca Maticic, Lucas WiessingBMC Infectious Diseases 2014, 14(Suppl 6):S16 (19 September 2014)

Review   Open Access

Hepatitis C in European prisons: a call for an evidence-informed response

Amber Arain, Geert Robaeys, Heino StöverBMC Infectious Diseases 2014, 14(Suppl 6):S17 (19 September 2014)

Roundtable   Open Access

Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis

Jeffrey V Lazarus, Jens Lundgren, Jordi Casabona, Lucas Wiessing, Catharina Matheï, Peter Vickerman, Maria Prins, Mirjam Kretzschmar, Maria Kantzanou, Isabelle Giraudon, Marica Ferri, Paul Griffiths, Magdalena Harris, Margaret Walker, Lilyana Chavdarova, Eberhard Schatz, Katrin Schiffer, John Kools, Jason Farell, Luís MendãoBMC Infectious Diseases 2014, 14(Suppl 6):S18 (19 September 2014)

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert